Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.
Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.
复制标题
炎症性肠病的分子分析：临床上有用的诊断、反应预测和靶向治疗监测工具。
DOI：
10.1007/s40291-015-0142-7
复制
发表时间：
2015
影响因子：
4
通讯作者：
Li,Xuhang
中科院分区：
文献类型：
--
作者：
Jiang,Weiwei;Li,Xuhang
炎症性肠病（IBD）的生物标志物是用于IBD诊断和/或预后以及疾病活动性和治疗反应评估的非侵入性或微创性测试。在这里，我们更新了IBD生物标志物的现状，包括血清学、粪便和遗传（DNA和microRNA [miRNA]）生物标志物。作为更新，经典的血清学生物标志物，包括ASCA， pANCA，抗ompc，抗cir，抗i2和其他抗多糖抗体，仅简要讨论。本文的重点是那些最近被发现或广泛表征的疾病，以及生物标志物的临床应用，特别关注疾病并发症的预测和活动评估、粘膜愈合和对治疗的反应。特别地，我们讨论了基于血液的生物标志物预测抗肿瘤坏死因子(TNF)-α治疗反应的效用，如抗-TNF -α抗体或抗药物抗体（ADA）和抗TNF -α谷水平。最近引起广泛关注的粪便生物标志物也得到了广泛的讨论，包括表征良好的钙保护蛋白和乳铁蛋白，以及最近表征的M2-PK、CHI3L1、neopterin、MMP-9和HMGB1。基因组和外显子组测序能够发现一些罕见但定义疾病的IBD易感基因，特别是那些与非常早期发病的IBD有关的基因，在遗传水平上为IBD诊断/预后提供罕见但非常有用的生物标志物。最后，我们简要总结了miRNA作为潜在IBD生物标志物的发现、表征和潜在意义。
Biomarkers of inflammatory bowel disease (IBD) are non-invasive or minimally invasive tests for IBD diagnosis and/or prognosis as well as assessment of disease activity and response to therapy. Here, we update the current status of IBD biomarkers, including serological, fecal, and genetic (DNA and microRNA [miRNA]) biomarkers. As an update, the classical serological biomarkers, including ASCA, pANCA, anti-OmpC, anti-Cbir, anti-I2, and other anti-glycan antibodies, are discussed only briefly. Emphasis in this article is given to those that have been recently identified or extensively characterized, as well as to the clinical utilities of biomarkers, with special attention to prediction of disease complication and activity assessment, mucosal healing, and response to therapies. In particular, we discuss the utilities of blood-based biomarkers predicting therapeutic response to anti-tumor necrosis factor (TNF)-α, such as anti-anti-TNFα antibodies or anti-drug antibodies (ADA) and trough level of anti-TNFα. Fecal biomarkers, which have recently attracted substantial attention, are also discussed extensively, including the well-characterized calprotectin and lactoferrin, as well as the recently characterized M2-PK, CHI3L1, neopterin, MMP-9, and HMGB1. Genome and exome sequencing enables the discovery of a number of rare yet disease-defining IBD-susceptible genes, particularly those involved in very early onset IBD, providing rare yet extremely useful biomarkers at genetic levels for IBD diagnosis/prognosis. Finally, we briefly summarize the discovery, characterization, and potential implications of miRNA as potential IBD biomarkers.